Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
Ewa Fiorentino-Rozek/ LinkedIn
Aug 31, 2025, 07:10

Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?

Ewa Fiorentino-Rozek, Head of Clinical Affairs at AliveDx, shared a post on LinkedIn:

“IVD of the Week: Blood Group Genotyping – Are We Ready for Routine Use? 

Blood group genotyping has come a long way in recent years. It started as a specialized tool for identifying rare donors and solving complex antibody cases, but it’s increasingly being talked about as part of routine blood bank practice.
Compared to traditional serology, genotyping can:
– Detect blood group variants that serology can miss
– Improve matching for patients who receive frequent transfusions (like those with sickle cell disease or thalassemia
– Help manage rare donor inventories more effectively

Yet despite all this progress, many labs still rely mostly on serological methods. Making genotyping a routine part of blood banking isn’t simple. There are real hurdles:
– Cost – both for instruments and ongoing reagents
– Integration – adapting workflows and training staff
– Data interpretation – translating genotyping results into clear transfusion decisions
– Guidelines – not all regions have clear recommendations on when or how to implement routine genotyping

I’d love to hear from colleagues across labs, blood services, and industry:
– Is your center already using genotyping routinely, or only for special cases?
– What barriers are slowing down broader adoption where you work?
– Do you think genotyping will become standard practice in the next five years—or is that still further off?

Let’s share real-world experiences and thoughts on how to bridge the gap between promise and practice in blood group genotyping.

________
Hi, I’m Ewa, and I help In Vitro Diagnostics companies bring innovative products to market.
Follow me for insights on IVD regulations, performance evaluation, and industry trends.”

Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?

Stay updated with Hemostasis Today.

Blood banking Blood Group Genotyping Hemostasis Today In Vitro Diagnostics IVD Innovation Laboratory Medicine Rare Donors Sickle Cell Thalassemia Transfusion Medicine
NewsFeed